Key Takeaways BSX's Q3 gross and operating margins improved on a favorable mix from EP and WATCHMAN growth.BSX's WATCHMAN sales jumped 35% with rising U.S. concomitant adoption and broader patient penetration.BSX's EP sales surged 63% as FARAPULSE adoption accelerated, supported by OPAL HDx system uptake.Boston Scientific (BSX) posted an adjusted gross margin of 71% in the third quarter of 2025, representing a 60-basis-point (bps) improvement compared to the prior-year period. The increase was mainly driven ...

2025年11月20日，全球医疗科技巨头 雅培 Abbott Laboratories 正式宣布，将以现金方式收购美国精准诊断公 司 Exact Sciences ，总对价约 210亿美元 （约合人民币1493亿）。该交易预计于2026年上半年完成，成为 Abbott近年来规模最大、影响最深远的一笔并购案。 消息发布后，Exact Sciences股价在美股盘前大涨超过30%，市值突破200亿美元。业内普遍认为，此次收购将 显著改变全球癌症筛查与分子诊断的竞争格局，也标志着Abbott在高增长诊断赛道的战略转型正式落地。 # 公 司背景 与 双 方 定 位 Abbott成立于1888年，是全球领先的综合医疗科技企业，业务涵盖营养品、医疗器械、心血管介入、糖尿病管 理与体外诊断等多个领域。过去十年，Abbott凭借i-STAT与ARCHITECT系列分析仪在体外诊断市场稳居前 列，但随着疫情红利消退，其核心诊断业务增长趋缓，公司亟需寻找新的高壁垒、高成长赛道以维持营收动 力。 Exact Sciences成立于1995年，总部位于美国威斯康星州麦迪逊，是全球非侵入性癌症筛查与精准诊断的领先 企业。公司依托分子检 ...

Suburban Chicago is a long way from Britain, but they’re still calling it a bloody good deal. Illinois-based healthcare giant Abbott Laboratories said Thursday that it agreed to buy cancer-screening specialist Exact Sciences and its breakthrough blood test for $21 billion. SUBSCRIBE:  Receive more of our free The Daily Upside newsletter. READ ALSO: Sun Belt Housing Market too Hot to Touch for First-Time Buyers and Walmart Keeps Fan-Favorite Status as Shoppers Tighten Purse Strings Match Made in Lab Heaven ...

来源：市场资讯 （来源：欧洲并购与投资） 雅培将以230亿美元收购Exact Sciences 这笔交易是今年生命科学领域最大的交易之一。它将使雅培进入快速增长的癌症筛查市场。Exact Sciences的产品线包括癌症筛查和诊断产品，包括Cologuard和Oncotype DX检测，以及用于多癌种早期 检测和分子残留疾病检测的尖端液体活检检测。Exact Sciences是开发能够早期检测多种癌症类型的血 液检测的公司之一，其竞争对手包括Grail、Guardant Health等公司。 尽管Cologuard在十多年前首次亮相，但Exact Sciences于今年春季开始推出Cologuard Plus。这个升级版 本在粪便DNA检测中增加了新的遗传生物标志物，以帮助提高其准确性。在液体活检领域，该公司后 来推出了Cancerguard，通过筛选单次血液样本中发现的DNA片段，该检测能够发现50多种不同类型的 癌症。该检测不针对乳腺癌或前列腺癌，但其目标是发现每年在美国被诊断出的新病例中超过80%的肿 瘤迹象，这些肿瘤包括胰腺癌、卵巢癌、肝癌、肺癌、食管癌和胃癌等侵袭性强且筛查选择有限的癌 症。与此同时 ...

Core Insights - Exact Sciences Corp. is being acquired by Abbott Laboratories for approximately $21 billion, with Abbott offering $105 per share to Exact Sciences' shareholders [2][8] - The U.S. cancer screening and precision oncology diagnostics market is valued at around $60 billion, with Exact Sciences reporting $851 million in revenue for Q3 and raising its full-year revenue forecast to between $3.22 billion and $3.235 billion [3][8] Company Overview - Exact Sciences specializes in cancer screening products, including Cologuard, and is expected to generate about $3 billion in revenue this year [8] - The company's shares rose 17% to just under $101, marking a significant increase of roughly 80% since the beginning of 2025 [9] Industry Context - The global cancer screening market was estimated to be worth over $100 billion last year, projected to grow at an annual rate of 6% to 8% due to increasing cancer diagnoses [6] - Approximately 2 million people in the U.S. and 20 million globally are diagnosed with cancer each year, driving demand for innovative cancer screening solutions [6]

Core Insights - Exact Sciences has been downgraded from a Buy to a Neutral rating by Guggenheim amid its acquisition by Abbott Laboratories [1][6] - Abbott Laboratories has agreed to acquire Exact Sciences for $105 per share, valuing the company at approximately $21 billion, with an enterprise value of about $23 billion including net debt [2][6] - Exact Sciences is projected to exceed $3 billion in revenue this year, with high-teens organic growth anticipated [3][6] Company Developments - The acquisition by Abbott is expected to close in the second quarter of 2026 and will enhance Abbott's revenue growth and gross margin immediately [2][3][6] - Exact Sciences is recognized for its innovative cancer diagnostics solutions, including Cologuard and Cancerguard, solidifying its strong market position [1][5] Market Performance - The stock price of Exact Sciences is currently at $101.29, reflecting a 17.53% increase, marking its highest price in the past year [4] - The market capitalization of Exact Sciences is approximately $19.19 billion, with a historical low of $38.81 over the past year [4]

For Exact Sciences (NASDAQ: EXAS), good news came in the form of an acquisition bid. Healthcare giant Abbott Labs (NYSE: ABT) entered into a definitive agreement with Exact Sciences to buy the cancer screening and diagnostic test specialist. Under the terms of the deal, Abbott will pay $105 per share for Exact Sciences, an amount that represents a 22% premium to the closing price of Exact Sciences shares on Wednesday afternoon before the acquisition bid. For Abbott, the combination will broaden its cancer d ...

Abbott Laboratories (NYSE:ABT) M&A Announcement November 20, 2025 09:00 AM ET Company ParticipantsVijay Kumar - Senior Managing DirectorDavid Roman - Managing DirectorRobert Ford - Chairman and CEOMike Comilla - VP of Investor RelationsPhil Boudreau - EVP of Finance and CFOTravis Steed - Managing Director of Equity ResearchConference Call ParticipantsLarry Biegelsen - Senior Medical Device Equity Research AnalystRobbie Marcus - Managing Director and Senior AnalystOperatorGood morning, and thank you for stan ...

Welcome to Yahoo Finance's special coverage of the September jobs report. I'm Julie Hyman and we are just moments away from the September payroll sprint. Let's get a check on stock futures ahead of those numbers.Of course, there is a big other factor to consider today when you're looking at stock futures and that is Nvidia and its blowout numbers are reported last night. That's setting NASDAQ futures higher by 1.6%. S&P and Dow futures are also participating and we'll see how the September jobs report affec ...

Core Insights - Abbott Laboratories has agreed to acquire Exact Sciences for $105 per share, totaling approximately $21 billion in equity value and an estimated enterprise value of $23 billion, marking the largest deal in the global healthcare sector this year [1][3]. Acquisition Details - The acquisition represents Abbott's largest deal in nearly a decade and its second-largest overall [3]. - Exact Sciences is known for its Cologuard test, which has been used for colorectal cancer screening 20 million times since FDA approval in 2014 [2]. - Abbott's CEO has indicated a strategy focused on mergers and acquisitions to enhance its diagnostics business [2]. Financial Considerations - Analysts suggest that Abbott could allocate up to $30 billion for debt-financed acquisitions, supported by a low leverage ratio of 1.3x and approximately $7 billion in annual free cash flow [3]. - The acquisition will involve absorbing Exact Sciences' estimated $1.8 billion in net debt [3]. Market Impact - The acquisition is expected to add a new growth vertical to Abbott's portfolio, enhancing its position in the $60 billion U.S. cancer screening and precision oncology diagnostics markets [4]. - Following the announcement, Exact Sciences' stock rose by 17.43% to $101.20, while Abbott's stock increased by 0.27% to $126.49 in premarket trading [7]. Future Projections - Exact Sciences is projected to generate over $3 billion in revenue by 2025, with an organic sales growth rate in the high teens [6]. - The deal is anticipated to close in the second quarter of 2026, potentially driving growth in Cologuard and margin expansion for Exact Sciences [6].